Complications of Diabetes: Progress, but Significant Challenges Ahead

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2015 Jan 9

PMID 25568873

Citations 9

Authors

Tahseen A Chowdhury

Shang Shaho

Ahmad Moolla

Affiliations

Soon will be listed here.

Citing Articles

HOXD9/APOC1 axis promotes macrophage M1 polarization to exacerbate diabetic kidney disease progression through activating NF-κB signaling pathway.

Feng Y, Zhang Y, Gao F, Liu M, Luo Y Hereditas. 2024; 161(1):40.

PMID: 39511608 PMC: 11542400. DOI: 10.1186/s41065-024-00345-9.

The Mitigatory Effect of Shen-Qi Compound on the Diabetic Thoracic Aortic Complications through Inhibiting the Inflammatory Microenvironment by miR-223-3p/RBP-J/IRF8 Axis.

Tian Y, Xu G, Gao H, Xie H, Leng Y, Fu X Evid Based Complement Alternat Med. 2022; 2022:6686931.

PMID: 36212957 PMC: 9534610. DOI: 10.1155/2022/6686931.

Correlation Among Self-Care Ability, Psychological Status, and Quality of Life in Discharged Patients with Hepatolithiasis Complicated with Diabetes Mellitus and T-Tube.

Huang C, Wang Y, Cai Y, Shen Z, Zhang H, Tan Z Front Surg. 2022; 9:907900.

PMID: 35651692 PMC: 9149299. DOI: 10.3389/fsurg.2022.907900.

Ferroptosis and ferritinophagy in diabetes complications.

He J, Li Z, Xia P, Shi A, FuChen X, Zhang J Mol Metab. 2022; 60:101470.

PMID: 35304332 PMC: 8980341. DOI: 10.1016/j.molmet.2022.101470.

Is the Duration of Diabetes Diseases Positively Associated With Knowledge About Diabetic Complications? Knowledge of Diabetes Mellitus Complications and Associated Factors Among Type-2 Diabetic Patients in Public Hospitals of Addis Ababa, 2020.

Chekol G, Mengistu D, Tadesse A Front Public Health. 2022; 9:812586.

PMID: 35265583 PMC: 8899007. DOI: 10.3389/fpubh.2021.812586.

References

Brugts J, Ninomiya T, Boersma E, Remme W, Bertrand M, Ferrari R . The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J. 2009; 30(11):1385-94. DOI: 10.1093/eurheartj/ehp103. View

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil H, Livingstone S . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5. View

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

Gaede P, Lund-Andersen H, Parving H, Pedersen O . Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358(6):580-91. DOI: 10.1056/NEJMoa0706245. View

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

Spijkerman A, Dekker J, Nijpels G, Adriaanse M, Kostense P, Ruwaard D . Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care. 2003; 26(9):2604-8. DOI: 10.2337/diacare.26.9.2604. View

10.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

11.

Mommersteeg P, Herr R, Pouwer F, Holt R, Loerbroks A . The association between diabetes and an episode of depressive symptoms in the 2002 World Health Survey: an analysis of 231,797 individuals from 47 countries. Diabet Med. 2013; 30(6):e208-14. DOI: 10.1111/dme.12193. View

12.

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

13.

Chowdhury T, Finer N . Preventing diabetes: a call for concerted national action. Clin Med (Lond). 2013; 13(4):328-9. PMC: 4954293. DOI: 10.7861/clinmedicine.13-4-328. View

14.

Ajjan R . Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diab Vasc Dis Res. 2012; 9(4):243-4. DOI: 10.1177/1479164112455534. View

15.

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

16.

Gregg E, Li Y, Wang J, Burrows N, Ali M, Rolka D . Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014; 370(16):1514-23. DOI: 10.1056/NEJMoa1310799. View